Oxygen Bonded Directly To Sulfur (e.g., Sulfoxides, Etc.) Patents (Class 514/708)
-
Patent number: 6572873Abstract: Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.Type: GrantFiled: November 22, 2000Date of Patent: June 3, 2003Assignee: BTG International LimitedInventors: Tariq Osman, Sheila Bronwen Flynn, David Dakin Iorwerth Wright, Anthony David Harman, Timothy David Boorman
-
Publication number: 20030087814Abstract: Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.Type: ApplicationFiled: November 4, 2002Publication date: May 8, 2003Inventor: Seth Lederman
-
Patent number: 6559181Abstract: This invention relates to new antiestrogens of the general formula in which the substituents have the meanings that are explained in more detail in the description. The new compounds are a) pure antiestrogens or b) antiestrogens with partial estrogenic action (tissue-selective estrogens). Based on these properties, the new compounds are suitable for the production of pharmaceutical agents: in the case of a), for example, for the treatment of breast cancer; in the case of b), for example, for hormone replacement therapy.Type: GrantFiled: November 7, 2000Date of Patent: May 6, 2003Assignee: Schering AktiengesellschaftInventors: Ulrich Klar, Rolf Bohlmann, Karsten Parczyk, Karl-Heinrich Fritzemeier, Monika Lessl, Rosemarie Lichtner
-
Patent number: 6531111Abstract: Disclosed are novel compositions for embolizing blood vessels which are particularly suited for treating vascular lesions via catheter delivery.Type: GrantFiled: May 19, 2000Date of Patent: March 11, 2003Assignee: Micro Therapeutics, Inc.Inventors: Thomas J. Whalen, II, Chinh N. Tran, Noah M. Roth, Richard J. Greff
-
Patent number: 6524624Abstract: A two-part disinfecting systems, as well as disinfecting compositions and methods for making and using the same. The two-part disinfecting system contains a first part and a second part adapted to be mixed to yield an aqueous disinfecting composition, wherein the first part comprises a chlorite and the second part comprises an acid and an optional oxidizable colorant, and wherein the first part, the second part, or both the first and second parts comprise an alpha olefin sulfonate.Type: GrantFiled: May 16, 2001Date of Patent: February 25, 2003Assignee: Alcide CorporationInventors: Joseph Morelli, C. Cayce Warf, Jr., Maura Aldrich, Cecilia Moser Morse, Jean Wiley
-
Publication number: 20030008925Abstract: The invention concerns the use for making medicines with waking effect in conditions of disorders affecting wakefulness related to morphine treatment of sulphinyl benzhydryl compounds of formula (I) in which: each of the cycles is substituted by one or several groups F, Cl, Br, CF3 , NO2, NH2, C1-C4 alkyl, C1-C4 alkoxy, methylenedioxy; R is —OH, H, C1-C4 alkyl C1-C4 hydroxyalkyl, or R1R2N—Y—, where Y is a hydrocarbon radical in C1-C4 with linear or branched chain; n is a whole number equal to 1, 2 or 3; and their additive salts when R comprises a basic radical. Said medicines enable to reduce sleepiness in patients without affecting the antalgic effect of morphine.Type: ApplicationFiled: May 18, 2000Publication date: January 9, 2003Inventors: Marc Esteve, Jacques Gertner
-
Publication number: 20020193357Abstract: A compound of formula (I): 1Type: ApplicationFiled: May 2, 2002Publication date: December 19, 2002Inventors: Ching Song, Shutsung Liao
-
Patent number: 6495607Abstract: Benzocycloheptenes of general formula I in which R1, R2 and Y have the meanings indicated herein, have antiestrogenic activity on and are suitable for the production of pharmaceutical agents, especially for prophylaxis and therapy of osteoporosis.Type: GrantFiled: July 19, 1999Date of Patent: December 17, 2002Assignee: Schering AGInventors: Rolf Bohlmann, Jorg Kroll, Hermann Kuenzer, Christa Hegele-Hartung, Monika Lessl, Rosemarie Lichtner, Yukishige Nishino
-
Publication number: 20020183333Abstract: Compositions and methods for chemotherapy are disclosed. The compositions and methods disclose herein are effective inhibitors of chemotherapy-induced nephrotoxicity, yet unexpectedly do not inhibit the antineoplastic activity of the chemotherapeutic compound. The chemotherapeutic compositions and methods of the invention comprise an inhibitor of catalytic iron. In a preferred embodiment, the inhibitor is a cytochrome P450 inhibitor and the chemotherapeutic compound is cisplatin.Type: ApplicationFiled: March 19, 2002Publication date: December 5, 2002Inventors: Sudhir V. Shah, Radhakrishna Baliga
-
Patent number: 6486210Abstract: Styryl benzylsulfones of formula I are useful as antiproliferative agents, including, for example, anticancer agents: wherein (a) (i) at least three of R1, R2, R3, R4 and R5 are independently selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl, and the balance of said R1, R2, R3, R4 and R5 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; and (ii) R6, R7, R8, R9 and R10 are independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkoxy, nitro, cyano, carboxyl, hydroxyl, phosphonato, amino, sulfamyl, acetoxy, dimethylamino(C2-C6 alkoxy) and trifluoromethyl; or (b) (i) at least three of R6, R7, R8, R9 and R10 are independently selected from theType: GrantFiled: April 12, 2001Date of Patent: November 26, 2002Assignee: Temple University—Of the Commonwealth System of Higher EducationInventors: E. Premkumar Reddy, M. V. Ramana Reddy
-
Publication number: 20020172704Abstract: A planting method for preventing pests, especially snails, is disclosed. The method includes the steps of (a) providing a biodegradable material, (b) adding a pesticide into the biodegradable material, and (c) spreading the pesticide-added biodegradable material on a plant-growing substrate. Therefore, a plant growing on the plant-growing substrate will not undergo the damage of pests.Type: ApplicationFiled: March 27, 2001Publication date: November 21, 2002Inventors: Shih-Pan-Yu Hsieh, Rui-Zhi Huang
-
Publication number: 20020169206Abstract: A class of substituted biphenyl compounds is described for use in treating inflammation and inflammation-related disorders.Type: ApplicationFiled: January 30, 2001Publication date: November 14, 2002Applicant: G.D. Searle & Co.Inventors: David B. Reitz, James J. Li, Monica B. Norton
-
Patent number: 6475466Abstract: Disclosed are methods for treating endoleaks arising from endovascular repair of abdominal aortic aneurysms. The disclosed methods involve the in situ sealing of endoleaks after placement of an endovascular prostheses in the abdominal aorta. Sealing of endoleaks is achieved by injection of either a biocompatible polymer or prepolymer fluid composition into the endoleak which composition in situ solidifies to seal the leak. Preferably, the biocompatible fluid composition comprises a contrast agent to allow the clinician to visualize the sealing process.Type: GrantFiled: March 20, 2000Date of Patent: November 5, 2002Assignee: Micro Therapeutics, Inc.Inventors: Charlie Ricci, Bart Dolmatch, Andrew H. Cragg, Richard J. Greff
-
Publication number: 20020132780Abstract: The present invention relates to compositions, kits, and methods utilized for the treatment of joint dysfunction, bone dysfunction, and/or inflammation. The composition utilized herein are useful for those mammals experiencing painful or debilitating joint, bone, or inflammatory conditions, and are particularly suited for mammals which are diabetic or at risk for diabetes, as well as those desiring or requiring conveniently dosed chondroprotective compositions having low carbohydrate content, low caloric value and/or having a low glycemic index.Type: ApplicationFiled: January 12, 2001Publication date: September 19, 2002Inventors: Matthew Thomas Heisey, Kenneth Norman Kern, Kris Eugene Spence
-
Patent number: 6444709Abstract: The invention relates to novel heteroethynylenic compounds having the general formula (I): as well as to the use of these compounds in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological complaints in particular), or alternatively in cosmetic compositions.Type: GrantFiled: February 7, 2000Date of Patent: September 3, 2002Assignee: Galderma Research & Development S.N.C.Inventors: Philippe Diaz, Jean-Michel Bernardon
-
Patent number: 6436444Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The .compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.Type: GrantFiled: September 26, 1997Date of Patent: August 20, 2002Assignee: Ecolab Inc.Inventors: Francis L. Richter, Cathy M. Paquette, Richard K. Staub
-
Patent number: 6414034Abstract: (Z)-styryl benzylsulfones of formula I are useful as anticancer agents: wherein R1 is selected from the group consisting of hydrogen, chloro and nitro; R2 is selected from the group consisting of hydrogen, lower alkyl, lower alkoxy, chloro, bromo, and fluoro; and R3 and R4 are independently selected from the group consisting of hydrogen, lower alkyl, nitro, chloro, bromo, and fluoro; provided that at least one of R1 or R2 is hydrogen. The corresponding (Z)-styryl benzylsulfides are useful as intermediates in the preparation of the biologically active (Z)-styryl benzyl sulfones.Type: GrantFiled: November 22, 2000Date of Patent: July 2, 2002Assignee: Temple University of the Commonwealth System of Higher EducationInventors: E. Premkumar Reddy, M. V. Ramana Reddy
-
Publication number: 20020068765Abstract: This invention describes the new benzocycloheptenes of general formula I 1Type: ApplicationFiled: July 19, 1999Publication date: June 6, 2002Inventors: ROLF BOHLMANN, JORG KROLL, HERMANN KUENZER, CHRISTA HEGELE-HARTUNG, MONIKA LESSL, ROSEMARIE LICHTNER, YUKISHIGE NISHINO
-
Patent number: 6368608Abstract: Novel pharmaceutically/cosmetically-active polyaromatic propynyl compounds have the structural formula (I): in which X is one of the radicals: and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.Type: GrantFiled: October 31, 2000Date of Patent: April 9, 2002Assignee: Centre International de Recherche Dermatologiques Galderma (C.I.R.D.)Inventor: Jean-Michel Bernardon
-
Patent number: 6344485Abstract: Methods of using prostaglandin agonists for the reduction of intraocular pressure, and accordingly glaucoma.Type: GrantFiled: June 18, 1999Date of Patent: February 5, 2002Assignee: Pfizer Inc.Inventors: Kimberly O. Cameron, Bruce A. Lefker
-
Publication number: 20010047038Abstract: A class of compounds which are (H+/K+)ATPase inhibitors can be used for the treatment of viral infections.Type: ApplicationFiled: June 20, 2001Publication date: November 29, 2001Inventors: Alan E. Moorman, Daniel P. Becker, Daniel L. Flynn
-
Patent number: 6291441Abstract: This invention relates to a method of treating patients suffering from the inflammatory bowel disorders. The method includes administering to a patient in need of treatment an effective amount of a thiol or reducible disulfide compound according to the formula set forth in the specification.Type: GrantFiled: September 27, 2000Date of Patent: September 18, 2001Inventors: Frederick H. Hausheer, Seetharamulu Peddaiahgari
-
Patent number: 6274632Abstract: The invention relates to compounds of the formula (I): CF2═CX—CH2—CH2—S(O)—R wherein X represents hydrogen, halogen or lower alkyl, and R represents a group OR1 or NR2R3 wherein R1, R2 and R3 are as defined in the description. The compounds are useful for controlling insect and like pests of agriculture.Type: GrantFiled: September 10, 1999Date of Patent: August 14, 2001Assignee: Zeneca LimitedInventor: Roger Salmon
-
Patent number: 6267952Abstract: The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates to the polymers employed in the methods described herein as well as novel intermediates and methods for preparing the polymers.Type: GrantFiled: October 5, 1998Date of Patent: July 31, 2001Assignee: GelTex Pharmaceuticals, Inc.Inventors: W. Harry Mandeville, III, Molly Kate Boie, Venkata R. Garigapati
-
Patent number: 6262038Abstract: A germicidal composition suitable for cleaning fruits, vegetables, skin and hair, includes a mixture of fruit acids and a surfactant. The surfactant may be an anionic surfactant (such as sodium lauryl sulfate), a sophorose lipid biosurfactant, or a combination of the two surfactants. The mixture of fruit acids may include citric acid, glycollic acid, lactic acid, malic acid and tartaric acid. The fruit acids are preferably present, in an aqueous solution, in a sufficient amount to produce a pH of about 2-6, for example 3.8-4.2. The compositions of the present invention are germicidal, and are sufficient to kill 100% of E. coli, Salmonella and Shigelia in 30 seconds after application to the surface of the object.Type: GrantFiled: April 16, 1999Date of Patent: July 17, 2001Assignee: David Christal, Ltd.Inventors: Deborah Pierce, Timothy J. Heilman
-
Patent number: 6239111Abstract: The present invention discloses the use, in the manufacture of a preventive and therapeutic drug of a brain disease, of a compound represented by formula (1): CH2═CH—CH2—S(O)n—R (1) [wherein R represents a hydrogen atom, an alkyl group, an alkenyl group, a substituted alkyl group, a substituted alkenyl group, an alkylthio group, an alkenylthio group, a phenyl group, a substituted phenyl group, a heterocyclic group, or a group derived from an amino acid or an oligopeptide by deletion of one hydrogen atom, and which group may have a protective group; and n is 0, 1, or 2], a glycoside thereof, or a salt of the compound or the glycoside. The drug of the present invention for ameliorating brain diseases, inhibiting reduction of brain neurons and promoting branching of neurites, is useful for the prevention and treatment of brain diseases such as dementia in association with degeneration and sloughing of brain neurons.Type: GrantFiled: January 26, 1998Date of Patent: May 29, 2001Assignee: Wakunaga Pharmaceutical Co., Ltd.Inventors: Toru Moriguchi, Hiromichi Matsuura, Hiroshi Saito
-
Patent number: 6166075Abstract: This invention relates to new antiestrogens of the general formula ##STR1## in which the substituents have the meanings that are explained in more detail in the description.The new compounds are a) pure antiestrogens or b) antiestrogens with partial estrogenic action (tissue-selective estrogens).Based on these properties, the new compounds are suitable for the production of pharmaceutical agents: in the case of a), for example, for the treatment of breast cancer; in the case of b), for example, for hormone replacement therapy.Type: GrantFiled: June 9, 1999Date of Patent: December 26, 2000Assignee: Schering AktiengesellschaftInventors: Ulrich Klar, Rolf Bohlmann, Karsten Parczyk, Karl-Heinrich Fritzemeier, Monika Lessl, Rosemarie Lichtner
-
Patent number: 6162815Abstract: Novel pharmaceutically/cosmetically-active polycyclic aromatic compounds having the structural formula (I): ##STR1## wherein Ar is a radical having one of the formulae (a)-(e): ##STR2## which are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders are provided. In particular, based on their RXR-agonist activity, these compounds may be used to treat noninsulin-dependent diabetes mellitus (NIDDM) and obesity.Type: GrantFiled: September 10, 1998Date of Patent: December 19, 2000Assignee: Centre International de Recherches Dermatologiques GaldermaInventor: Jean-Michel Bernardon
-
Patent number: 6162445Abstract: Novel pharmaceutically/cosmetically-active polyaromatic propynyl compounds have the structural formula (I): in which X is one of the radicals: ##STR1## and are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of mammalian skin and hair conditions/disorders.Type: GrantFiled: October 6, 1997Date of Patent: December 19, 2000Assignee: Centre International de Recherches Dermatologiques GaldermaInventor: Jean-Michel Bernardon
-
Patent number: 6156784Abstract: Disclosed are compositions containing compounds of the formula (I) below wherein A,B,C,G,Q and R are defined herein. The compounds are useful as phosphotyrosine mimics that, when incorporated into an appropriate molecular structure, inhibit the binding of tyrosine kinase-dependent regulatory proteins to their native phosphotyrosine-containing ligands or receptors. Also disclosed are methods for preparing the compounds of the formula (I).Type: GrantFiled: December 7, 1999Date of Patent: December 5, 2000Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Rajashekhar Betageri, Jean-Marie Ferland, Montse Llinas-Brunet, Neil Moss, John R. Proudfoot
-
Patent number: 6150415Abstract: Biologically stable inhibitors of soluble epoxide hydrolases are provided. The inhibitors can be used, for example, to selectively inhibit epoxide hydrolase in therapeutic applications such as treating inflammation, for use in affinity separations of the epoxide hydrolases, and in agricultural applications. A preferred class of compounds for practicing the invention have the structure shown by Formula 1 ##STR1## wherein X and Y is each independently nitrogen, oxygen, or sulfur, and X can further be carbon, at least one of R.sub.1 -R.sub.4 is hydrogen, R.sub.2 is hydrogen when X is nitrogen but is not present when X is sulfur or oxygen, R.sub.4 is hydrogen when Y is nitrogen but is not present when Y is sulfur or oxygen, R.sub.1 and R.sub.3 are each independently a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, acyl, or heterocyclic, or being a metabolite or degradation product thereof.Type: GrantFiled: February 18, 1999Date of Patent: November 21, 2000Assignee: The Regents of the University of CaliforniaInventors: Bruce D. Hammock, Christophe H. Morisseau, Jiang Zheng, Marvin H. Goodrow, Tonya Severson, James Sanborn
-
Patent number: 6110504Abstract: An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and albumin which is buffered by lactate and has a pre-administration pH of between 5 and 6.5 is disclosed. Also disclosed is an artificial plasma-like solution having at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplimentation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. The plasma-like solution including cryoprotective adducts is also disclosed.Type: GrantFiled: February 17, 1998Date of Patent: August 29, 2000Assignee: Biotime, Inc.Inventors: Paul E. Segall, Harold D. Waitz, Hal Sternberg, Judith M. Segall
-
Patent number: 6103753Abstract: An intimal thickening inhibitory agent comprising, as an active ingredient, a compound represented by formula (1): ##STR1## wherein X represents an oxygen atom or a group of formula (2): ##STR2## wherein n represents an integer of from 0 to 2, R.sub.1 represents a hydrogen atom or an acyl group; R.sub.2 represents a hydrogen atom, a lower alkyl group or a lower alkenyl group; R.sub.3 represents a lower alkyl group; and R.sub.4, R.sub.5, and R.sub.6, which may be the same or different, each represent a hydrogen atom or a substituted or unsubstituted alkyl group; or R.sub.3 and R.sub.4 may be taken together to form a 5-membered ring; or R.sub.5 and R.sub.6 may be taken together to form a cycloalkyl group; provided that R.sub.6 is nil when R.sub.3 and R.sub.4 are taken together to form benzofuran or benzo[b]thiophene.Type: GrantFiled: May 6, 1998Date of Patent: August 15, 2000Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Osamu Cynshi, Reiko Sekimori, Yoshiaki Kato
-
Patent number: 6075044Abstract: The use of certain heterocyclic derivatives for treating parasitic protozoa infections in mammals, in particular bovine trichomoniasis and giardiasis, is disclosed.Type: GrantFiled: July 17, 1998Date of Patent: June 13, 2000Assignee: The Regents of the University of CaliforniaInventors: Ching C. Wang, John Somoza, Jon P. Page, Ronaldus Marcellus Alphonsus Knegtel, Irwin D. Kuntz, Connie M. Oshiro, A. Geoffrey Skillman
-
Patent number: 6060083Abstract: A method for treating palmar-plantar erythrodysethesia syndrome includes applying to affected areas a therapeutically effective amount of a dimethyl sulfoxide solution.Type: GrantFiled: April 1, 1999Date of Patent: May 9, 2000Assignee: Topical Technologies, Inc.Inventors: Robert T. Dorr, David S. Alberts
-
Patent number: 6020343Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.Type: GrantFiled: June 15, 1998Date of Patent: February 1, 2000Assignee: Merck Frosst Canada, Inc.Inventors: Michel Belley, Jacques Yves Gauthier, Erich Grimm, Yves LeBlanc, Chun-Sing Li, Michel Therien, Cameron Black, Petpiboon Prasit, Cheuk-Kun Lau, Patrick Roy
-
Patent number: 6020382Abstract: The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.Type: GrantFiled: January 4, 1999Date of Patent: February 1, 2000Assignee: Merck & Co., Inc.Inventors: Thomas W. Doebber, Joel P. Berger, Gregory D. Berger, Mark D. Leibowitz, David E. Moller, John T. Olson, Arthur A. Patchett, Richard B. Toupence
-
Patent number: 5981602Abstract: The present invention relates to the use of ajoene for inhibiting integrin-mediated cell-cell fusion. Specific types of cell-cell fusion are giant multinucleated cell formation, syneytia formation, and osteoclast formation.Type: GrantFiled: January 11, 1996Date of Patent: November 9, 1999Assignee: John B. DavidsonInventors: Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
-
Patent number: 5973010Abstract: A composition and method for treating epidermal wounds utilizes an aqueous solution of sodium sulphate, sodium carbonate, sodium bicarbonate, sodium chloride and ichthammol.Type: GrantFiled: May 15, 1998Date of Patent: October 26, 1999Inventor: Robert L. Crawford
-
Patent number: 5932621Abstract: The present invention relates to the use of Ajoene to treat integrin-mediated tumors and metastasis.Type: GrantFiled: May 19, 1995Date of Patent: August 3, 1999Assignee: John B. DavidsonInventor: Alexander V. Tatarintsev
-
Patent number: 5932196Abstract: The present invention are for emulsion compositions and the process for making such compositions containing biological and cosmetic actives subject to hydrolysis of actives during processing and storage of the emulsion composition. Buffers are incorporated into emulsion at a point wherein the acidic and basic conditions created during processing have little effect on compositions.Type: GrantFiled: November 4, 1994Date of Patent: August 3, 1999Assignee: The Procter & Gamble CompanyInventors: Curtis Bobby Motley, Patricia Sue Raleigh
-
Patent number: 5883134Abstract: Disclosed is a method of controlling or inhibiting the growth of microorganisms comprising introducing in, at, or on a locus an antimicrobially effective amount of an antimicrobially active nitroethene compound.Type: GrantFiled: August 21, 1996Date of Patent: March 16, 1999Assignee: Rohm and Haas CompanyInventors: Adam Chi-Tung Hsu, Peter Osei-Gyimah, Barry C. Lange, Rhoda W. Joseph
-
Patent number: 5863954Abstract: The progression of infection and other pathologies produced by a viral infection may be inhibited by administering an effective dosage of Ajoene. Additionally, Ajoene has anti-tumor, anti-shock, and anti-inflammation effects. In general, Ajoene may be used to treat any integrin-mediated disease or condition.Type: GrantFiled: January 11, 1996Date of Patent: January 26, 1999Assignee: John B. DavidsonInventors: Alexander V. Tatarintsev, Ali S. Turgiev, John B. Davidson
-
Patent number: 5851988Abstract: Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formula ##STR1## whereineach A is independently a proton-accepting substituent;each R is independently a noninterfering substituent;n is 0, 1, or 2; andeach linker is independently an isostere of --NHCONH-- or of --N.dbd.N-- or of --NHCO--.Compounds in the genus of Formula (1) can also be used for structure activity studies to identify features responsible for the relevant activities.Type: GrantFiled: January 15, 1997Date of Patent: December 22, 1998Assignee: Terrapin Technologies, Inc.Inventors: Richard Sportsman, Hugo O. Villar, Lawrence M. Kauvar, Wayne R. Spevak
-
Patent number: 5847008Abstract: The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.Type: GrantFiled: January 31, 1997Date of Patent: December 8, 1998Assignee: Merck & Co., Inc.Inventors: Thomas W. Doebber, Joel P. Berger, Gregory D. Berger, Mark D. Leibowitz, David E. Moller, John T. Olson, Arthur A. Patchett, Richard B. Toupence
-
Patent number: 5840991Abstract: The invention relates to novel compounds of formula (I) ##STR1## wherein R.sub.1 represents hydrogen, hydroxy or alkoxy;R.sub.2, R.sub.3, R.sub.4 and R.sub.5 may be hydrogen or alkyl; andn is 0,1 or 2;and the pharmaceutically acceptable salts thereof.The invention also relates to the processes for preparing the compounds of formula (I), and the pharmaceutical compositions containing them, and their use as a low density lipoprotein peroxidation inhibitors, anti-atherosclerotic agents and/or antihyperlipidemic agents.Type: GrantFiled: September 17, 1997Date of Patent: November 24, 1998Assignee: Development Center for BiotechnologyInventors: Feng-Wen Yeng, Shan-Shue Wang, Jaw-Yuh Chiu, Chin-Fen Lee, Chia-Lin J. Wang
-
Patent number: 5807899Abstract: This invention describes the new triphenylethylenes of general formula I ##STR1## in which n means an integer from 1 to 10,R' means a sulfur-containing organic radical,R" means a hydrogen atom, an iodine atom or a hydroxy groups,E means a hydrogen atom,G means a hydrogen atom orE and G together mean a methylene bridge.The new compounds have strong antiestrogenic properties and are suitable for the production of pharmaceutical agents, for example for treating breast cancer.Type: GrantFiled: July 5, 1996Date of Patent: September 15, 1998Assignee: Schering AktiengesellschaftInventors: Rolf Bohlmann, Joseph Heindl, Hermann Kunzer, Yukishige Nishino, Karsten Parczyk, Martin Schneider
-
Patent number: 5679695Abstract: The present invention relates to a method of treating a retrovirus utilizing a compound of the formula(R.sub.2).sub.n R.sub.1 --Ar--X--Y--R(T.sub.1)(T.sub.2).sub.m IThe present invention also relates to pharmaceutical compositions in which the active ingredient has a compound of formula I.Type: GrantFiled: January 25, 1995Date of Patent: October 21, 1997Assignee: The University of ConnecticutInventor: Frederick William Wassmundt
-
Patent number: 5676962Abstract: Injectable microfoam for scleroteraphy. The sclerotherapy of varices is based on the injection of liquid substances capable of suppressing them. The present invention relates to the preparation of sclerosing substances in the form of a microfoam. The microfoam is prepared with sclerosing agents, and is then injected in the vein to be treated, so that the microfoam displaces the blood contained in the vein and provides for the contact of the sclerosing agent with the vascular endothelium, with a predetermined known concentration and during a controllable time.Type: GrantFiled: February 23, 1995Date of Patent: October 14, 1997Inventors: Juan Cabrera Garrido, Juan Cabrera Garcia-Olmedo
-
Patent number: 5672626Abstract: A class of substituted spirodienes is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula II: ##STR1## wherein each of R.sup.1, R.sup.2, R.sup.4 and R.sup.5 is hydrido; wherein R.sup.3 is methylsulfonyl or sulfamyl; and wherein each of R.sup.6 through R.sup.10 is independently selected from hydrido, halo, alkyl, alkoxy, alkylthio, cyano, haloalkyl, haloalkoxy, hydroxyalkyl, alkoxyalkyl, hydroxyl, and mercapto; and wherein n is 1, 2 or 3; or a pharmaceutically-acceptable salt thereof.Type: GrantFiled: July 9, 1996Date of Patent: September 30, 1997Assignee: G. D. Searle & Co.Inventors: Horng-Chih Huang, David R. Reitz